Dyne Therapeutics, Inc. (DYN)
D
Pipeline Grade
Financial Position (from SEC Filings)
$755.5M
Cash & Equivalents
$144.9M
Quarterly Burn Rate
16 mo
Est. Cash Runway
$3,872M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT03458832 | Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD | OTHER | Active Not Recruiting | 324 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-03 | 8-K | Dyne Therapeutics, Inc. (DYN) (CIK 0001818794) - EX-99.1 | EDGAR |